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May 19 this year marked World Hep-
atitis Day [1].This event does not usually
make the headlines in the same way that
World AIDS Day does, but viral hepatitis
affects about half a billion people globally
(perhaps one in 12 of the global popula-
tion), and so the relative publicity associ-
ated with World Hepatitis Day does not
accurately reflect the importance of hep-
atitis as a public health problem.
The two major hepatitis viruses—hepa-
titis C virus (HCV) and hepatitis B virus
(HBV)—share a number of features. Both
viruses are readily spread through the
transfer of infected blood or blood prod-
ucts. Both cause persistent infections and
share an insidious progression after decades
of asymptomatic carriage that creates a
huge burden of end-stage liver disease and
liver cancer. Thus, both viruses are major
public health problems across the globe.
However, there are substantial differences
between these infections in terms of the risk
groups affected, the geographical distribu-
tion of the viruses, and the tools at our
disposal to deal with them.
Prospects for Controlling HBV
and HCV
For HBV we have a well-established
vaccine and an emerging panel of well-
tolerated oral agents for the treatment of
chronic infection. Although there is still a
massive burden of complex and severe
infection to tackle, the pathway towards
effective combination therapy has already
been trodden in HIV, and careful clinical
trials in this area for HBV should bring
some clarity. Delivery of such drug
combinations in resource-poor settings
where the prevalence of carriage is high
will create its own significant challenges.
For HCV we have no current vaccine,
and current therapies are toxic, complex,
and expensive, as well as only partially
effective. Treatment is further complicated
by HIV coinfection, which is increasingly
encountered in some risk groups [2]. So
why is the prevention and treatment of
HCV infections apparently so far behind
that of HBV infections? One reason is that
HCV was only identified in 1989, and
only successfully cultured in 2005 [3,4].
However, the major biological hurdle to
controlling HCV is the huge diversity of
the virus, both within patients and among
populations [5].
HCV is an RNA-based virus with a
variable genome and the capacity to
evolve over time to evade drug and
immunologic pressure. HCV has co-
evolved with human populations for
centuries, if not millennia [6], and has
diversified widely over this period
(Figure 1). By comparison, the phyloge-
netic tree of HIV is much more compact
because this virus has had less than a
century in which to diversify in humans.
The net result of this diversification is
the existence of seven major genotypes of
HCV (the last added very recently) that
share less than 80% sequence homology
with one another, and more than 50 HCV
subtypes [7]. Although these genotypes
may have arisen over long periods as
endemic strains in geographically distinct
regions (e.g., genotype 6 in southeast Asia
[8]), most have now spread globally.
Genotype 1 is particularly common in
western Europe and the United States,
although genotype 3 is also now very
common in the United Kingdom as a
result of its spread through intravenous
drug-using populations and through im-
migration from the Indian subcontinent.
Multiple genotypes occur in many other
viruses, including HBV, but their impor-
tance in HCV is particularly high because
both the duration and success rate of
current treatments for HCV infection
(pegylated interferon-alpha and ribavirin)
are highly genotype dependent. Thus,
genotypes 2 and 3 are typically associated
with much greater response rates than
genotypes 1 and 4 (70%–80% long-term
clearance versus 40%–50%) and require
shorter treatment periods (six months
versus one year) [9]. The biological basis
for these differences is unclear—the ge-
nomes of these genotypes are so diverse
that such differences could result from
multiple complex changes. Even within a
single genotype (e.g., genotype 1), the
fundamental mechanisms behind relative
resistance to treatment of different HCV
subtypes are not fully defined, although an
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Drexler JF, Kupfer B, Petersen N,
Grotto RMT, Rodrigues SMC, et al.
(2009) A novel diagnostic target in
the hepatitis C virus genome. PLoS
Med 6(2): e1000031. doi:10.1371/
journal.pmed.1000031
Christian Drosten and colleagues
develop, validate, and make openly
available a prototype hepatitis C
virus assay based on the conserved
39 X-tail element, with potential for
clinical use in developing countries.
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has been described [10].
The Role of Nucleic Acid Tests
for HCV
Given these important clinical and
virologic differences between HCV geno-
types, robust and sensitive nucleic acid
tests for HCV have a major role to play in
virus detection and in guiding treatment
and thus are at the core of current clinical
practice in developed countries. However,
these tests are relatively complex molecu-
lar tests and are therefore not universally
available. Additionally, they may not be
equally sensitive at detection of all geno-
types. In a recent article in PLoS Medicine,
however, Christian Drosten and col-
leagues described a new approach to
nucleic acid testing in HCV [11].
The authors generated a test based on a
highly conserved region in the 39 end of
the virus (most current tests are based on
the 59 end) and validated their assay to
show that it was sensitive in detection of a
wide range of genotypes from geographi-
cally diverse populations. They also at-
tempted to reduce the overall cost of their
approach and have thus provided a novel
system that uses an open (i.e., non-
proprietary) protocol that might be partic-
ularly appropriate for resource-poor set-
tings. This new assay is potentially an
important step forward for laboratories in
such regions and, if rolled out effectively,
could provide novel information relevant
to the prevalence, clinical impact, and
treatment response of HCV genotypes
that are currently poorly studied—most
clinical analyses, and vaccine and treat-
ment trials have focused on genotype 1.
Although very simple and cost-effective
tests to detect, quantify, or genotype HCV
in resource-poor areas could be of great
Figure 1. Complete genome trees of the hepatitis C virus, HIV-1 (M-group), and the hemagglutinin region of influenza A. Nucleotide
sequences were randomly selected from their respective databases representing each of the major subtypes from each virus [17–19]. Only non-
recombinant genomes were included. Maximum likelihood trees were built using GARLI (Genetic Algorithm for Rapid Likelihood Inference, available
at http://www.nescent.org/). Trees have been drawn to the same scale.
doi:10.1371/journal.pmed.1000096.g001
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usefulness of any such test in comparison
to other methods and in relation to other
public health priorities in such regions will
need to be considered carefully. Thus,
although conventional PCR methods as
used by Drosten and colleagues look
promising, non-PCR-based methods such
as loop-mediated isothermal amplification
(LAMP) also need to be considered, since
little specialist equipment is required for
LAMP and the sensitivity appears to be
high [12]. In the end, however, the
definitive test for any new method of
HCV analysis will be clinical utility in the
field.
The Extreme Viral Diversity of
HCV
As we mark World Hepatitis Day, the
recent paper by Drosten and colleagues
once more draws our attention to one of
the key features of HCV: its extreme viral
diversity, which brings enormous chal-
lenges for the future. The capacity for
HCV to evolve creates a complex target
for both vaccine and drug development.
Nevertheless, recent advances in both
these areas provide some cautious hope
for the future—at least in the case of
genotype 1 infection [13,14]. Key to
successful vaccine development will be
the generation of effective, sustained, and
broad anti-HCV immune responses. How-
ever, the immune responses to non-
genotype 1 viruses are very poorly de-
scribed, and recent data suggest that there
is relatively little overlap between immune
responses to genotypes 1 and 3. Thus, at
present it is unclear whether HCV vac-
cines against specific genotypes will pro-
vide any cross-protection against other
genotypes [15]. The situation with drugs
may be even more complex, with pre-
existing diversity even within genotype 1
already providing some level of drug
resistance [16].
Future studies of the diverse HCV
genotypes that exist globally—hopefully
facilitated by the recently published meth-
ods—will, therefore, help us understand
the overall clinical impact of HCV in
affected populations and will determine
our potential to intervene. Since HCV
emerged from the shadows 20 years ago, it
has shown itself to be ‘‘smarter than the
average virus.’’ Thus, it may take longer
than 20 years for us to put it back into the
shadows, and it will probably take all our
efforts to do so.
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